Latest Biotech News

OMass Therapeutics closed an oversubscribed $310 million Series C to advance its lead ACTH-pathway inhibitor OMS1620 into Phase II for congenital adrenal hyperplasia (CAH) and ACTH-dependent...

AstraZeneca struck a large AI-enabled target-discovery collaboration with insitro focused on liver and heart disease programs. The deal underscores how large pharmas are formalizing partnerships...

Iambic Therapeutics, an AI-enabled cancer drug developer, priced a $150 million IPO to fund clinical development of internally discovered oncology programs. The company’s strategy is to use...

The FDA announced a “Rare Disease Framework Initiative” aimed at reimagining how it regulates therapies for rare diseases, shifting from a one-size-fits-all approach to condition-specific...

Regeneron presented early efficacy data for ubamatamab in advanced low-grade serous ovarian cancer (LGSOC), a biologically distinct subtype with limited treatment options. In a late-breaking IGCS...

An open-label pilot trial reported that a single fecal microbiota transplantation (FMT) dose cleared adherent-invasive E. coli from the gut lining in all evaluable Crohn’s disease patients who...

A proteomic analysis from the phase 1/2a delandistrogene moxeparvovec study found that high-dose AAV gene therapy triggered a sharp but self-limiting immune response in treated boys, with no...

Researchers developed and validated a simple five-point clinical score to predict 28-day mortality in children with septic shock. Built from four variables available within 24 hours of pediatric...

A case report described direct angiographic visualization of coronary air embolism after atrial fibrillation catheter ablation, with a suspected atrioesophageal fistula as the underlying cause....

Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, has assumed control of cell therapies after the company—now known as Lakefront Biotherapeutics—divested in a strategic...

The FDA announced a “Rare Disease Framework Initiative” aimed at reworking how it regulates therapies for rare diseases. Under the plan, the agency intends to move away from one-size-fits-all...

OMass Therapeutics closed an oversubscribed $310 million Series C to advance its endocrinology and immunology programs. The company said the bulk of proceeds will support OMS1620 through Phase II...

AstraZeneca signed an AI-enabled target discovery deal with insitro, expanding the UK pharma’s use of machine-learning systems for drug discovery. The arrangement provides insitro with funding to...

Osivax said its lead influenza vaccine failed in a Phase 2b trial, prompting a pivot to a combination strategy. After the unsuccessful mid-stage readout, the French biotech plans to pair the...

Verastem disclosed early clinical data for VS-7375, a KRAS inhibitor designed to target the G12D mutation, and the company framed the results as supporting progression into multiple late-stage...

Stryker announced a major commercial and strategic deal with CMR Surgical, providing roughly $400 million in investment and an option structure that could enable a future acquisition subject to...

A comprehensive evidence map reviewing 73 AI studies in radiopharmaceutical therapy found strong technical performance across segmentation, dosimetry, and prediction tasks. However, it reported no...

An observational analysis using target trial emulation suggests that initiating vasopressin very early in septic shock—within three hours of norepinephrine escalation—may reduce 28-day mortality....

A Canadian pilot study reported that FET-PET/MRI identified significantly larger metabolically active tumor volumes than conventional MRI in more than half of high-grade glioma patients. The...

Illumina launched its BioInsight platform, a unified software environment designed to bring multiomics analysis tools, AI capabilities, and curated resources into a single workflow. The company...